Ultra Rapid Detoxification (UROD)
Customize your policy alerts
Sign up for Aetna Policy 0317 alerts
Get alerted when Policy 0317 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance on ultra rapid detoxification (UROD) for opioid detoxification and related indications; applies to providers and claims adjudicators handling detoxification services for Aetna members.
No material clinical or coverage changes in this revision.
Coverage Determinations
Coverage stance — Experimental and Investigational
Covered when ALL of the following are met:
The following ICD-10 diagnosis code ranges are identified in this Clinical Policy Bulletin as not covered for the indications addressed: F11.10–F11.19 (opioid abuse), F11.20–F11.29 (opioid dependence), and the listed poisoning and adverse-effect codes in the T40.x group (including but not limited to T40.0X1+–T40.4X4+, T40.601+–T40.604+, T40.691+–T40.694+, and the adverse-effect subcodes such as T40.0X5+, T40.3X5+, T40.605+, and T40.695+).
Anesthesia-assisted or heavy-sedation ultra rapid opioid detoxification (UROD) is regarded as not medically sound because published evidence and guideline reviews report serious harms and do not demonstrate benefit. Sources note reports of serious adverse events — including deaths associated with anesthetic use and risks such as aspiration during anesthesia — and systematic reviews and guideline recommendations state that the potential harms and lack of demonstrated effectiveness do not support offering anesthesia-assisted or heavy-sedation UROD.
Coding and Billing
| J2310 | Injection, naloxone HCl, per 1 mg [not covered when used for UROD] |
| J2311 | Injection, naloxone hydrochloride (zimhi), 1 mg [not covered when used for UROD] |
| F11.10 - F11.19 | Opioid abuse |
| F11.20 - F11.29 | Opioid dependence |
| T40.0X1+ - T40.4X4+ | Poisoning by opiates and related narcotics (various subcodes listed) |
| T40.0X5+ T40.2X5+ T40.4X5+ T40.605+ T40.695+ | Adverse effects of other opiates and related narcotics |
| T40.3X5+ | Adverse effects of methadone |
Provider Responsibilities and Authorization
Prior authorization — investigational treatment
Aetna considers ultra rapid detoxification (UROD) experimental and investigational and therefore not a covered service; prior authorization does not make investigational services covered.
- Relevant HCPCS codes identified in the policy (e.g., J2310, J2311) are listed as not covered when used for UROD.
Prior authorization (no requirements stated)
No prior authorization requirements for UROD are specified in the extracted sections of this Clinical Policy Bulletin.
Preferred detoxification approaches
Clinical guidance supports established detoxification approaches — gradual withdrawal combined with medication and long-term psychosocial support — rather than anesthesia-assisted or heavy sedation UROD.
- Proven detoxification involves gradual withdrawal plus medication and long-term psychosocial support.
- Guidelines and systematic reviews recommend against anesthesia-assisted rapid or ultra-rapid detoxification due to lack of benefit and risk of serious harms.
No specified provider action
No additional provider action or requirement is specified in the extracted policy content for this inventory item.
Safety and evidence documentation
Document the evidence in the clinical record if UROD is considered, including reported safety concerns, lack of demonstrated effectiveness, and referenced guideline recommendations against anesthesia-assisted UROD.
- Include documentation of reported serious adverse events (including deaths) associated with anesthesia-assisted UROD.
- Reference guideline statements (e.g., NICE, UpToDate) noting that anesthesia-assisted rapid/ultra-rapid detoxification is not recommended.
Available Aetna resources
Members and providers can access Aetna resources (glossary, mobile app, accessibility services, legal notices, FAQs, program provisions, privacy and nondiscrimination notices) via the links listed in the policy's Additional Information section.
- Glossary and Aetna Mobile App links are provided.
- Legal notices, privacy center, FAQs, program provisions, and accessibility services links are listed.
Experimental/investigational — triggers denial
Services for ultra rapid detoxification (UROD), and associated administration/billing (e.g., J2310, J2311 when used for UROD), are considered experimental/investigational and are not covered; claims for these services may be denied.
- ICD-10 diagnosis codes listed for opioid abuse/dependence and opioid poisoning (F11.x; T40.x ranges) are identified in the policy as not covered for the CPB indications.
- J2310 and J2311 are noted as not covered when used for UROD.
External link disclaimer
Links to non-Aetna websites are provided for convenience only; Aetna is not responsible for the content, accuracy, or privacy practices of linked sites.
- External site content may not be controlled by Aetna and should not be relied on as Aetna policy guidance.
Clinical Background
Detoxification is an initial step in treating opioid use disorder, but it is not by itself a cure. Established, proven approaches emphasize a gradual withdrawal followed by medication-assisted treatment and long-term psychosocial support to reduce the risk of relapse. UROD differs by using rapid, antagonist-precipitated withdrawal under general anesthesia or heavy sedation with intensive care monitoring, and evidence does not establish its safety or superior long-term effectiveness compared with standard, medication-supported detoxification approaches.
Key Definitions
Treatment Approaches
Medication-assisted detoxification / Psychosocial support
Accepted treatment modalities:
Preferred over anesthesia-assisted or heavy sedation UROD due to lack of evidence of safety and effectiveness and reports of serious adverse events including death.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.